Most Popular
Newsletter
Breaking News
Cyagen Announces Support of Rare Genomic Institute’s BeHEARD Competition – Rare Disease Science Technology Grants Challenge
May 18, 2020
Cyagen Biosciences has committed to donate up to $83,250 of mouse model vector construction services as prizes for the Rare Genomic Institute’s BeHEARD (Helping Empower and Accelerate Research Discoveries) Challenge, which provides technology and financial grants for rare disease research. Read More >
Newsletter
Breaking News
Expanded Knockout Catalog Models – Over 10k Genes Now Available
Mar 24, 2020
In our continuing efforts to expand the gene knockout models offered in the Cyagen Knockout Catalog, described in our recent Technical Bulletin, we are proud to announce the availability of over 10,000 KO mouse models. Read More >
Research Trend
Breaking News
White Paper
COVID-19
Coronaviruses and SARS-CoV-2 – Host Receptor-Mediated Infection Mechanisms & Potential Antiviral Treatments
Mar 10, 2020
At the end of 2019, a large-scale illness broke out from Wuhan, Hubei Province - a central province of China. The virus that cased this illness could enter the respiratory tract through droplets - moreover, the increasingly busy traffic conditions and travel around the holiday season made the virus spread extremely rapidly. Read More >
Research Trend
Breaking News
White Paper
COVID-19
Beyond ACE2: Additional Targets of Significance for Coronavirus Research
Mar 10, 2020
At present, the prevention and treatment of coronavirus is the most urgent issue for scientific and medical research. In addition to the ACE2 host receptor target that is being highly focused on, what other targets deserve the attention of current coronavirus researchers? Read More >
Newsletter
Breaking News
Cyagen Knockout Catalog Models Now Available in the US & Europe
Mar 04, 2020
As the leader in custom genetically engineered mouse and rat models, Cyagen has generated thousands of custom knockout (KO), knockin (KI), and transgenic rodent lines for its customer base that covers over 2,000 universities and companies worldwide. This rapid growth has seen the number of publications citing Cyagen in high-impact journals such as Nature, Cell and Science increase to over 3,400 in record time. Read More >
Breaking News
Cyagen Closes $41 Million Series B to Expand Animal Research Model Business
Feb 27, 2020
Cyagen Biosciences Suzhou Inc. closed a 285 million RMB (equivalent to about $41 million USD) Series B financing as of Feb 25. The investments are from funds managed by CMS Capital, GF Qianhe and GF Xinde which are both wholly owned by GF securities, and Guanghua Investment respectively. Read More >
Research Trend
Breaking News
White Paper
COVID-19
White Paper: Infectivity and Immune Mechanisms of Coronaviruses & SARS-CoV-2
Feb 27, 2020
An outbreak of COVID-19 (Coronavirus Disease in 2019) caused by the novel coronavirus, officially named SARS-CoV-2, swept across the world from Wuhan at the end of 2019 - having since brought a huge impact on the lives of people both in China and abroad. Read More >
Breaking News
CRISPR-Pro: How the Patent Dispute has Transformed Science Innovation
Sep 10, 2019
As CRISPR-based innovations begin to move into clinical testing and the dispute over core patents continues worldwide, CRISPR-Pro gene editing has been under increased scrutiny in both commercial and academic sectors. Read More >
Breaking News
CRISPR-modified mice have widespread and unexplained mutations
Jun 01, 2017
The advent of CRISPR-mediated genome-editing has revolutionized the generation of genetically modified animal models. In the few short years since... Read More >